NO20033732L - N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser. - Google Patents

N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.

Info

Publication number
NO20033732L
NO20033732L NO20033732A NO20033732A NO20033732L NO 20033732 L NO20033732 L NO 20033732L NO 20033732 A NO20033732 A NO 20033732A NO 20033732 A NO20033732 A NO 20033732A NO 20033732 L NO20033732 L NO 20033732L
Authority
NO
Norway
Prior art keywords
compounds
pharmaceutical compositions
substituted non
nr2b antagonists
aryl heterocyclic
Prior art date
Application number
NO20033732A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033732D0 (no
Inventor
Christopher F Claiborne
John W Butcher
David A Claremon
Brian E Libby
Nigel J Liverton
Peter M Munson
Kevin T Nguyen
Brian Phillips
Wayne Thompson
John A Mccauley
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23034191&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033732(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20033732D0 publication Critical patent/NO20033732D0/no
Publication of NO20033732L publication Critical patent/NO20033732L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
NO20033732A 2001-02-23 2003-08-22 N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser. NO20033732L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27110001P 2001-02-23 2001-02-23
PCT/US2002/005226 WO2002068409A1 (en) 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Publications (2)

Publication Number Publication Date
NO20033732D0 NO20033732D0 (no) 2003-08-22
NO20033732L true NO20033732L (no) 2003-10-22

Family

ID=23034191

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033732A NO20033732L (no) 2001-02-23 2003-08-22 N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.

Country Status (33)

Country Link
US (2) US7217716B2 (de)
EP (1) EP1379520B2 (de)
JP (1) JP4179879B2 (de)
KR (1) KR100849839B1 (de)
CN (1) CN100567293C (de)
AT (1) ATE324371T1 (de)
AU (1) AU2002252053B2 (de)
BG (1) BG108113A (de)
BR (1) BR0207526A (de)
CA (1) CA2438895A1 (de)
CZ (1) CZ20032258A3 (de)
DE (1) DE60210944T3 (de)
DK (1) DK1379520T3 (de)
EA (1) EA005974B1 (de)
EC (1) ECSP034744A (de)
EE (1) EE200300403A (de)
ES (1) ES2261658T3 (de)
GE (1) GEP20063741B (de)
HR (1) HRP20030669A2 (de)
HU (1) HUP0303258A3 (de)
IL (2) IL157254A0 (de)
IS (1) IS6902A (de)
MX (1) MXPA03007621A (de)
NO (1) NO20033732L (de)
NZ (1) NZ527365A (de)
PL (1) PL364625A1 (de)
PT (1) PT1379520E (de)
SI (1) SI1379520T1 (de)
SK (1) SK10542003A3 (de)
UA (1) UA75392C2 (de)
WO (1) WO2002068409A1 (de)
YU (1) YU64303A (de)
ZA (1) ZA200306159B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399160A4 (de) * 2001-06-12 2004-08-25 Merck & Co Inc Nr2b-rezeptor-antagonisten zur behandlung oder prävention von migräne
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2003087089A1 (fr) 2002-04-16 2003-10-23 Teijin Limited Derives de piperidine possedant un antagonisme de ccr3
CN100360521C (zh) 2002-04-25 2008-01-09 帝人株式会社 具有ccr3拮抗作用的4,4-二取代的哌啶衍生物
JP2004315511A (ja) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
DK1648882T3 (da) * 2003-06-04 2008-11-24 Merck & Co Inc 3-fluor-piperidiner som NMDA/NR2B-antagonister
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
ES2315834T3 (es) 2004-02-03 2009-04-01 Astrazeneca Ab Derivados de quinazolina.
AU2005271669A1 (en) * 2004-08-03 2006-02-16 Merck & Co., Inc. 1,3-disubstituted heteroaryl NMDA/NR2B antagonists
EP1797036A1 (de) * 2004-09-10 2007-06-20 UCB Pharma, S.A. Sigma-rezeptor-liganden
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JP2009520756A (ja) * 2005-12-21 2009-05-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ α２Ｃアドレナリン受容体アンタゴニストとしての置換されたピラジノン誘導体
EP2520567A3 (de) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Mit cyclischen Gruppen substituierte, stickstoffhaltige heterocyclische Derivate
WO2007126841A2 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5179509B2 (ja) * 2006-12-08 2013-04-10 エフ．ホフマン−ラ ロシュ アーゲー 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008128996A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
SI2148873T1 (sl) * 2007-04-23 2013-01-31 Janssen Pharmaceutica, N.V. Derivati 4-alkoksipiridazina kot antagonisti receptorja dopamina 2 s hitro disociacijo
JP4691669B2 (ja) * 2007-08-22 2011-06-01 アストラゼネカ・アクチエボラーグ シクロプロピルアミド誘導体
EP2215073A4 (de) * 2007-10-31 2011-04-06 Merck Sharp & Dohme Schlafmodulation mit nr2b-rezeptorantagonisten
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
ES2444128T3 (es) 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
JP5417439B2 (ja) 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
CA2730774C (en) 2008-07-31 2016-09-13 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
RU2012136921A (ru) * 2010-02-18 2014-03-27 Астразенека Аб Твердые формы, содержащие производные циклопропиламида
MX336333B (es) * 2010-02-18 2016-01-15 Astrazeneca Ab Nueva forma cristalina de un derivado de ciclopropilbenzamida.
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
ES2571741T3 (es) * 2011-03-31 2016-05-26 Bayer Ip Gmbh Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
EP2760856B1 (de) * 2011-09-30 2016-09-14 Bristol-Myers Squibb Company Selektive nr2b-antagonisten
JP6042968B2 (ja) 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
JP2016028017A (ja) * 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
WO2015182724A1 (ja) * 2014-05-28 2015-12-03 トーアエイヨー株式会社 置換トロパン誘導体
TW201609741A (zh) * 2014-06-04 2016-03-16 盧郡控股（開曼）有限公司 作為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之二氟乙基吡啶衍生物
ES2723436T3 (es) * 2014-09-15 2019-08-27 Rugen Holdings Cayman Ltd Derivados de pirrolopirimidina como antagonistas del receptor NMDA NR2B
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
CA3187499A1 (en) * 2015-05-11 2016-11-17 Eric George KLAUBER Process for preparing 4-amino-pyridazines
TWI721987B (zh) 2015-06-01 2021-03-21 開曼群島商盧郡控股（開曼）有限公司 做為nr2b nmda受體拮抗劑之3,3-二氟哌啶胺基甲酸酯雜環化合物
EP3544610A1 (de) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Behandlung von autistischen erkrankungen, zwangsneurosen und angststörungen
PT3589632T (pt) * 2018-02-23 2020-12-09 Fraunhofer Ges Forschung Novos inibidores de glutaminil ciclases bacterianas para utilização no tratamento de doenças periodontais e relacionadas

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL265777A (de) 1960-06-09
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
WO1984001151A1 (en) * 1982-09-24 1984-03-29 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
US5356905A (en) 1990-02-06 1994-10-18 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
ES2146578T3 (es) 1990-05-10 2000-08-16 Pfizer Indolona neuroprotectora y derivados relacionados.
US5189036A (en) 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
JPH0788355B2 (ja) 1991-04-18 1995-09-27 フアイザー・インコーポレイテツド フェノール性２―ピペリジノ―１―アルカノールのプロドラグエステル
PL169884B1 (pl) 1991-07-17 1996-09-30 Pfizer Sposób wytwarzania nowych pochodnych 2-(4-hydroksypiperydyno)-1-alkanolowych PL PL PL
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69332860T2 (de) 1992-12-21 2004-03-11 Smithkline Beecham Corp. Bicyklische fibrinogen antagoniste
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1994020062A2 (en) 1993-03-03 1994-09-15 Eli Lilly And Company Balanoids as protein kinase c inhibitors
AU679045B2 (en) 1993-03-18 1997-06-19 Merck Sharp & Dohme Limited Benzimidazole derivatives
AU3138595A (en) 1994-07-20 1996-02-16 Acea Pharmaceuticals, Inc. Haloperidol analogs and the use thereof
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0742208A1 (de) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamid-Derivate
JPH11505828A (ja) 1995-05-26 1999-05-25 ファイザー・インコーポレーテッド パーキンソン症候群の治療用の選択的ｎｍｄａアンタゴニスト含有組合せ
DE69620974T2 (de) 1995-11-06 2003-01-16 Kuraray Co Verfahren zur Herstellung von Acetalen
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0787493A1 (de) 1996-02-03 1997-08-06 F. Hoffmann-La Roche Ag Tetrahydroisochinolin-Derivate
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU2898297A (en) 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
PL190866B1 (pl) 1996-07-25 2006-02-28 Biogen Inhibitor adhezji komórek, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0846683B1 (de) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxypiperidinderivate
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
AU1415099A (en) 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
AU772373B2 (en) 1998-08-07 2004-04-22 Laboratoires Serono Sa FSH mimetics for the treatment of infertility
DE19838300A1 (de) 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CZ20013678A3 (cs) 1999-04-13 2002-07-17 Basf Aktiengesellschaft Ligandy integrinového receptoru
EP1206260A4 (de) 1999-06-30 2002-10-30 Merck & Co Inc Src-kinase hemmende verbindungen

Also Published As

Publication number Publication date
HUP0303258A3 (en) 2004-06-28
EE200300403A (et) 2003-12-15
US7053089B2 (en) 2006-05-30
ZA200306159B (en) 2004-07-05
CA2438895A1 (en) 2002-09-06
ES2261658T3 (es) 2006-11-16
UA75392C2 (en) 2006-04-17
IL157254A0 (en) 2004-02-19
NZ527365A (en) 2005-08-26
KR20030076703A (ko) 2003-09-26
NO20033732D0 (no) 2003-08-22
GEP20063741B (en) 2006-02-10
CN1503793A (zh) 2004-06-09
DK1379520T3 (da) 2006-08-21
IS6902A (is) 2003-07-31
DE60210944T3 (de) 2015-07-23
JP4179879B2 (ja) 2008-11-12
IL157254A (en) 2008-11-26
KR100849839B1 (ko) 2008-08-01
DE60210944T2 (de) 2007-04-19
EP1379520B1 (de) 2006-04-26
SI1379520T1 (sl) 2006-08-31
HRP20030669A2 (en) 2005-06-30
US7217716B2 (en) 2007-05-15
HUP0303258A2 (hu) 2004-01-28
WO2002068409A1 (en) 2002-09-06
YU64303A (sh) 2006-05-25
PT1379520E (pt) 2006-08-31
US20020165241A1 (en) 2002-11-07
JP2004524314A (ja) 2004-08-12
BG108113A (bg) 2005-04-30
MXPA03007621A (es) 2003-12-04
AU2002252053B2 (en) 2006-09-14
PL364625A1 (en) 2004-12-13
EA005974B1 (ru) 2005-08-25
EA200300919A1 (ru) 2004-02-26
US20040209889A1 (en) 2004-10-21
ATE324371T1 (de) 2006-05-15
SK10542003A3 (sk) 2004-03-02
CN100567293C (zh) 2009-12-09
CZ20032258A3 (cs) 2004-01-14
EP1379520B2 (de) 2014-04-09
ECSP034744A (es) 2003-10-28
EP1379520A1 (de) 2004-01-14
DE60210944D1 (de) 2006-06-01
AU2002252053C1 (en) 2002-09-12
BR0207526A (pt) 2004-03-09

Similar Documents

Publication Publication Date Title
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
DK1076644T3 (da) N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
DK1263722T3 (da) Farmaceutiske sammensætninger, som indeholder azetidinderivat, nye azetidinderivater og fremstilling deraf
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20052182L (no) Nye forbindelser
NO20050828L (no) lndol-3-svovelderivater
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
NO20054787D0 (no) Indenderivater som farmasotiske midler
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE0101932D0 (sv) Pharmaceutical combinations
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
GB0308201D0 (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application